Hims & Hers has set ambitious targets for 2030, with plans to achieve a 22.5% compound annual growth rate in revenue and approximately 33% EBITDA CAGR. The company reaffirmed its weight management guidance despite changes in its relationship with Wegovy, a weight management drug. As the company continues to expand its product offerings and partnerships, investors are closely monitoring these developments to gauge future profitability and growth potential. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.